Zafirlukast

Drug Profile

Zafirlukast

Alternative Names: Accolate; Accolate SR; Accoleit; Aeronix; Azimax; ICI 204219; Olmoran; Respix®; Vanticon; Zafirst

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Class Antiallergics; Antiasthmatics; Tosyl compounds
  • Mechanism of Action Leukotriene D4 receptor antagonists; Leukotriene E4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Asthma

Most Recent Events

  • 21 Nov 2010 Generic equivalent available in USA for Asthma
  • 18 Nov 2010 Generic equivalent approved in USA for Asthma
  • 27 Feb 2001 3 case reports of severe hepatitis have been added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top